Jagannathan P, et al. - A double-blinded randomized controlled trial between June 2014 and May 2017 was conducted to test the premises that children born to mothers given intermittent preventive treatment (IPT) of malaria in pregnancy with dihydroartemisinin-piperaquine (IPTp-DP) would have a lower incidence of malaria during infancy vs children born to mothers who received intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP). Researchers reported that preventing malaria in pregnancy with IPTp-DP in the context of chemoprevention with dihydroartemisinin-piperaquine (DP) during infancy did not lead to a decreased incidence of malaria in childhood, and may be correlated with a higher risk of malaria and Plasmodium falciparum infection in infancy, but only in female infants. Small sample size and childhood provision of DP every 12 weeks in infancy were the main limitations.